Patents by Inventor Yong Hee RHEE

Yong Hee RHEE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical composition and methods comprising immune cells and ponatinib
    Patent number: 11504396
    Abstract: Methods and compositions for treating cancer are disclosed. The compositions comprise immune cells pretreated with ponatinib, or immune cells co-administered with ponatinib, where ponatinib promotes survival and anti-cancer cytotoxicity of the immune cells.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 22, 2022
    Assignee: NKMAX Co., Ltd.
    Inventors: Tae-gyun Kim, Yong-hee Rhee, Sang-min Oh
  • Method using expression of LIN28 for preparing stem cells having excellent renewal ability and therapeutic capacity
    Patent number: 11339196
    Abstract: The present invention relates to a cell therapeutic agent comprising a stem cell expressing Lin28, a pharmaceutical composition comprising a stem cell expressing Lin28 for the prevention or treatment of a neurological disorder, a bone disorder, a muscular system disorder, an epithelium-related disorder or a blood-related disorder, and a method for treating a neurological disorder, a bone disorder, a muscular system disorder, an epithelium-related disorder or a blood-related disorder using the composition. A stem cell excellent in terms of differentiation potency to various tissue cells and renewal ability can be prepared by introducing Lin28, which regulates an embryonic development procedure, or a vector expressing Lin28 during stem cell culturing, and by culturing the cell.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: May 24, 2022
    Assignee: Industry-University Cooperation Foundation Hanyang University
    Inventors: Sang-Hun Lee, Yong Hee Rhee, Chang-Hwan Park, Mi-Yoon Chang, Yanuar Alan Sulistio, Ji Yun Ko
  • Method of producing natural killer cells and composition for treating cancer
    Patent number: 11066644
    Abstract: A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3?/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3?/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: July 20, 2021
    Assignee: NKMAX Co., Ltd.
    Inventors: Sang Woo Park, Yong Man Kim, Jae Seob Jung, Yong-Hee Rhee
  • METHOD OF PRODUCING NATURAL KILLER CELLS AND COMPOSITION FOR TREATING CANCER
    Publication number: 20210032597
    Abstract: A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3?/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3?/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.
    Type: Application
    Filed: September 1, 2020
    Publication date: February 4, 2021
    Inventors: Sang Woo Park, Yong Man Kim, Jae Seob Jung, Yong-Hee Rhee
  • METHOD OF PRODUCING NATURAL KILLER CELLS AND COMPOSITION FOR TREATING CANCER
    Publication number: 20200172869
    Abstract: A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3?/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3?/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.
    Type: Application
    Filed: January 27, 2020
    Publication date: June 4, 2020
    Inventors: Sang Woo Park, Yong Man Kim, Jae Seob Jung, Yong-Hee Rhee
  • PHARMACEUTICAL COMPOSITION AND METHODS COMPRISING IMMUNE CELLS AND PONATINIB
    Publication number: 20200085870
    Abstract: Methods and compositions for treating cancer are disclosed. The compositions comprise immune cells pretreated with ponatinib, or immune cells co-administered with ponatinib, where ponatinib promotes survival and anti-cancer cytotoxicity of the immune cells.
    Type: Application
    Filed: December 19, 2017
    Publication date: March 19, 2020
    Inventors: Tae-gyun Kim, Yong-hee Rhee, Sang-min Oh
  • Method of producing natural killer cells and composition for treating cancer
    Patent number: 10590385
    Abstract: A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3?/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3?/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: March 17, 2020
    Assignee: NKMAX CO., LTD.
    Inventors: Sang Woo Park, Yong Man Kim, Jae Seob Jung, Yong-Hee Rhee
  • METHOD OF PRODUCING NATURAL KILLER CELLS AND COMPOSITION FOR TREATING CANCER
    Publication number: 20190345449
    Abstract: A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3?/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3?/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.
    Type: Application
    Filed: July 26, 2019
    Publication date: November 14, 2019
    Inventors: Sang Woo Park, Yong Man Kim, Jae Seob Jung, Yong-Hee Rhee
  • METHOD USING EXPRESSION OF LIN28 FOR PREPARING STEM CELLS HAVING EXCELLENT RENEWAL ABILITY AND THERAPEUTIC CAPACITY
    Publication number: 20190010197
    Abstract: The present invention relates to a cell therapeutic agent comprising a stem cell expressing Lin28, a pharmaceutical composition comprising a stem cell expressing Lin28 for the prevention or treatment of a neurological disorder, a bone disorder, a muscular system disorder, an epithelium-related disorder or a blood-related disorder, and a method for treating a neurological disorder, a bone disorder, a muscular system disorder, an epithelium-related disorder or a blood-related disorder using the composition. A stem cell excellent in terms of differentiation potency to various tissue cells and renewal ability can be prepared by introducing Lin28, which regulates an embryonic development procedure, or a vector expressing Lin28 during stem cell culturing, and by culturing the cell.
    Type: Application
    Filed: July 13, 2018
    Publication date: January 10, 2019
    Inventors: Sang-Hun LEE, Yong Hee RHEE, Chang-Hwan PARK, Mi-Yoon CHANG, Yanuar Alan SULISTIO, Ji Yun KO